Swedish CDMO recognised for its commitment to its French operations
The Prix D'Excellence Awards ceremony - Thomas Eldered, Recipharm CEO collecting their award.
Recipharm's four French facilities now serve over 50 of its customers worldwide, including a number of top 20 pharma firms.
Recipharm has received the “le Prix d’Excellence 2017 - Spécial Sciences de la vie” in recognition for its commitment to its French operations. The award was presented by the Swedish Chamber of Commerce in France.
The award acknowledges examples of best practice in the Franco-Swedish business community. As part of the application process, Recipharm was assessed on its commercial success, profitability, technological innovation, quality and continued commitment to its operations in France.
Over the course of its 10-year history in France, Recipharm has increased its presence significantly and its operations in the country now account for 21% of the company’s overall sales, with 73% of those sales being exported across the globe.
Recipharm, which established its French operations in 2007, now operates four manufacturing facilities in the country, located in Fontaine-les-Dijon, Pessac, Monts and Kaysersberg. From these facilities, the CDMO provides a broad range of development and manufacturing services across areas including solid dosage formulation, sterile injectables manufacturing and blow-fill-seal capabilities to a global customer base.
Jean-François Hilaire, Executive Vice President Strategy and Global Integration at Recipharm said: “We established our French operations 10 years ago to cater for demand in Europe and offer easy market access to our customers. Since then we have acquired four sites and made substantial investments into our facilities, including an EUR 18 million investment in 2016 into our blow-fill seal capability in Kaysersberg to meet customer demand in the US, Turkey, Australia and Canada."
“Our French facilities now serve over 50 of our customers worldwide, including a number of top 20 pharma firms, and employ over 20% of our staff. We have ongoing plans to grow our operations in the country and hope to see this positive trajectory continue for many years to come.”
Thomas Eldered, CEO at Recipharm added “I am honoured that Recipharm has been acknowledged for our decade-long commitment to France. We have been very pleased with the development of our business there and I would like to thank the Swedish Chamber of Commerce in France for recognising this.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.